Cartridge for liquid infusion apparatus
    13.
    发明授权
    Cartridge for liquid infusion apparatus 失效
    液体输液装置用墨盒

    公开(公告)号:US4140117A

    公开(公告)日:1979-02-20

    申请号:US798507

    申请日:1977-05-19

    摘要: A removable cartridge that is used in combination with a liquid drug infusion apparatus that comprises a housing that defines an inlet and outlet and has a recess for receiving the cartridge, a confined flow passageway extending between the inlet and outlet, and a conduit extending from the outlet to the infusion site. The removable cartridge includes: a hollow shell that fits within the recess, is adapted to contain the liquid drug, and has an outlet that is adapted to communicate with the inlet of the housing and the drug contained within the shell; pressure means within the shell that maintains a constant, positive pressure on the drug; and lock means on the shell that engages the housing to reversibly lock the cartridge within the recess.

    摘要翻译: 一种与液体药物输注装置组合使用的可拆卸的药筒,其包括限定入口和出口的壳体,并且具有用于接收药筒的凹部,在入口和出口之间延伸的限制流动通道和从所述入口和出口延伸的导管 出口到输液部位。 所述可拆卸的盒包括:适合于所述凹槽内的中空壳,适于容纳所述液体药物,并具有适于与所述壳体的入口和所述壳体内的药物连通的出口; 壳内的压力意味着对药物保持恒定的正压力; 以及壳体上的锁定装置,其与壳体接合以将盒可逆地锁定在凹部内。

    Transdermal delivery system for sufentanil
    17.
    发明授权
    Transdermal delivery system for sufentanil 有权
    舒芬太尼透皮给药系统

    公开(公告)号:US08252320B2

    公开(公告)日:2012-08-28

    申请号:US11888661

    申请日:2007-07-31

    摘要: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.

    摘要翻译: 提供了通过皮肤施用舒芬太尼的透皮递送系统。 当施用于受试者时,该系统含有足量的舒芬太尼以诱导和保持恒定的止痛状态。 该系统的特征在于具有一个或多个特征,其包括对来自系统的舒芬太尼的通量的高剂量形式速率控制,来自系统通过皮肤的舒芬太尼的高净通量,缺乏渗透促进剂, 优异的剪切时间,来自系统的舒芬太尼的净通量的低变异系数,高的输送效率和来自系统的舒芬太尼的稳定的稳态净通量。 还提供了使用透皮递送系统施用足够量的舒芬太尼以在施用于受试者时延长期间诱导和维持止痛的方法。

    Transdermal delivery system for sufentanil

    公开(公告)号:US08252319B2

    公开(公告)日:2012-08-28

    申请号:US11888650

    申请日:2007-07-31

    摘要: Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided.

    Biodegradable implants with controlled bulk density
    19.
    发明申请
    Biodegradable implants with controlled bulk density 审中-公开
    具有可控堆积密度的可生物降解植入物

    公开(公告)号:US20090123518A1

    公开(公告)日:2009-05-14

    申请号:US12288537

    申请日:2008-10-20

    IPC分类号: A61F2/00 A61K38/22

    摘要: Disclosed solid water permeable implants that include a water permeable polymer and an osmotically active drug formulation that comprises a drug; wherein the solid water permeable implant has a ratio R of bulk density of the solid water permeable implant to osmotic pressure of the drug formulation wherein R is greater than about 0.244 grams/milliliter-atm. Also disclosed are methods of making and using such solid water permeable implants.

    摘要翻译: 公开的固体水可渗透植入物,其包括水可渗透聚合物和包含药物的渗透活性药物制剂; 其中固体水可渗透植入物具有固体水可渗透植入物的体积密度与药物制剂的渗透压的比R,其中R大于约0.244克/毫升。 还公开了制造和使用这种固体水可渗透植入物的方法。